Biotech Values

[DewDiligence]

SHPG offers to acquire BXLT for $30.6B in stock:

http://www.wsj.com/articles/shire-offers-to-buy-baxalta-for-30-billion-1438688992

The offer comes just more than a month after Baxalta, which sells treatments for rare bleeding disorders and immune deficiencies, completed its spinoff from Baxter International Inc. Baxter remains Baxalta’s biggest shareholder, with a stake of about 24%, according to FactSet.

…Under the proposed deal, Baxalta holders would receive 0.1687 Shire American depositary shares for each Baxalta share held, implying a value of $45.23 per Baxalta share and a premium of 36% based on Monday’s closing prices. …the proposed deal would leave Baxalta shareholders with roughly 37% in the combined company.

…According to Shire, Baxalta had declined to engage in substantial talks regarding the proposal, which Shire said it first proposed in early July.